ARTICLE | Company News
FluGen, WARF deal
June 14, 2010 7:00 AM UTC
The foundation granted FluGen exclusive, worldwide rights to develop and commercialize FG 101 to treat influenza. WARF will receive an undisclosed upfront payment and is eligible for undisclosed miles...